Four Questions Every Pharma and CRO Leader Should Ask Before Buying an AI Platform

Key takeaways:  

• Conversations with vendors around artificial intelligence (AI) move fast. Demos are impressive. The questions that actually predict whether a platform will deliver, or disappoint, rarely come up until after the contract is signed. 
• The most important questions aren’t about the AI. They’re about the data beneath it, the scientific rigor behind it, the integration architecture around it, and the outcomes it has produced. 
• These four questions won’t slow the evaluation down. They’ll tell you faster whether a vendor is worth the investment. 

This blog series has spent six posts building a framework for understanding why clinical AI underperforms and what separates the organizations getting real results from those still waiting for the investment to pay off. Start there, if you’re coming here first. 

This post applies that framework to a specific moment: the vendor evaluation. Because the gap between a compelling demo and a platform that delivers tends to open up in the questions that don’t get asked. 

Here are the four that matter most. 

Question 1: Where do the data come from, and can you trace every element back to its source?

This is the question most evaluation teams skip because vendors rarely make data provenance the centerpiece of their pitch. They lead with the AI: the model sophistication, the prediction accuracy, the natural language interface. The data is presented as a given. 

It shouldn’t be.

As the earlier posts in this series established, AI performance is a direct function of data quality. And data quality is impossible to evaluate without knowing where the data came from, how they were prepared, and whether you can trace every output back to its source. Two data characteristics hinge on this question: quality and transparency. 

What a strong answer looks like: direct sourcing from healthcare organizations, not aggregation through opaque third parties; a clear explanation of how data are normalized, harmonized, and clinically validated; and full provenance visibility (the ability to trace any data element to its originating institution and the transformations applied to it). 

What to watch for: vendors who can describe their model architecture in detail but deflect or generalize when asked about data sourcing and preparation. That asymmetry is a signal. 

Question 2: How current are the data, and how quickly does new data become usable?

Static datasets degrade. Treatment patterns evolve. Patient populations shift. Site capabilities change as staff and infrastructure turn over. A feasibility prediction built on data that’s six months, 12 months, or two years old is a prediction about a clinical landscape that no longer exists. 

This matters for every AI use case in clinical development, but it matters most for feasibility and site selection, where predictions that don’t reflect current patient availability produce recruitment targets that can’t be hit. 

What a strong answer looks like: a living data network with continuous refreshes; a clear timeline from data generation at a healthcare institution to availability for analysis; and a demonstrated track record of feasibility predictions that align with actual enrollment reality.

What to watch for: vendors who describe their data as “regularly updated” without specifying what that means. Monthly? Quarterly? Annually? In a landscape where care patterns can shift significantly in months, the refresh cadence matters. 

Question 3: Can you link AI performance improvements directly and specifically to data quality?

This question separates vendors who understand why their platform works from vendors who know that it works, and it’s a meaningful distinction. 

Any vendor can point to customer results. The question is whether they can explain the mechanism: why did feasibility accuracy improve, why did that trial’s eligible patient pool expand, why did that recruitment model outperform the baseline? If the answer traces back to specific improvements in data comprehensiveness, recency, or clinical validation rather than to model upgrades or configuration changes, that’s evidence of genuine data-quality advantage. 

It also matters for reproducibility. Results that are explained are results you can plan around. Results that happened but can’t be accounted for are harder to rely on for program planning. 

What a strong answer looks like: customer outcomes that are clearly and specifically linked to data quality improvements, with quantified results in the areas that matter to your programs: feasibility accuracy, eligible patient pool size, recruitment conversion rates, protocol amendment rates. 

What to watch for: outcome claims that aren’t contextualized. Knowing that a trial achieved better enrollment is useful. Knowing that it did so because the data were comprehensive enough to identify a patient population that traditional criteria missed is what lets you evaluate whether the same outcome is achievable for your programs. 

Question 4: Can the platform integrate into our existing systems, and is it designed for where AI is going, not just where it is today?

As the previous post in this series covered, the highest-performing AI implementations aren’t the ones with the most sophisticated platforms. They’re the ones whose platforms deliver intelligence where decisions are already being made.  

This question has two parts. The first is practical: can the platform connect to the clinical operations systems your teams already use (protocol authoring tools, site management platforms, feasibility planning systems) without requiring those systems to be replaced or a parallel workflow to be built alongside them? 

The second is strategic: is the platform’s architecture designed with autonomous AI in mind? Today’s clinical AI assists human decision-making. The next generation will act more autonomously, and the organizations that will benefit from that evolution are the ones whose data infrastructure and platform architecture are already built for it. [We’ll cover what autonomous AI means for clinical operations specifically in the next post in this series.] 

What a strong answer looks like: API architecture that enables integration with existing systems; demonstrated implementations where real-world data (RWD) intelligence is embedded directly in clinical operations workflows; and a clear articulation of how the platform’s design supports the evolution toward more autonomous AI. 

What to watch for: platforms that require new interfaces and new workflows for every new capability, with integration treated as a future roadmap item rather than a current architectural priority. 

These four questions won’t make vendor conversations shorter. They’ll make them more honest, and they’ll surface the information that actually predicts whether a platform will deliver. 

About Asad Basir 

Asad serves as Vice President of Product at TriNetX, where he leads the development of the company’s product roadmap. He is focused on translating customer needs and market insights into solutions that help life sciences and healthcare organizations unlock the value of real-world data and advance clinical research across the drug development lifecycle.